Clinical trial
Open-Label study of bevacizumab (Avastin�) and taxane monotherapy for the first-line treatment of patients with advanced triple-negative breast cancer
Tolerability and safety profile of bevacizumab when combined with weekly paclitaxel as first line treatment of metastatic triple negative breast cancer.
| Category | Value |
|---|---|
| Study start date | 2009-10-01 |